Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.1182 | 1 | 1 |
Brugia malayi | Hypothetical zinc metalloproteinase T16A9.4 | 0.0109 | 0.0478 | 0.5 |
Echinococcus granulosus | endothelin converting enzyme 1 | 0.0109 | 0.0478 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 0.0478 | 1 |
Brugia malayi | Peptidase family M13 containing protein | 0.0109 | 0.0478 | 0.5 |
Toxoplasma gondii | cathepsin CPC2 | 0.0448 | 0.3492 | 0.3166 |
Echinococcus multilocularis | endothelin converting enzyme 1 | 0.0109 | 0.0478 | 0.5 |
Mycobacterium ulcerans | zinc metalloprotease | 0.0109 | 0.0478 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0243 | 0.0667 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.1182 | 1 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.1182 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0243 | 0.0667 |
Toxoplasma gondii | cathepsin CPC1 | 0.1182 | 1 | 1 |
Mycobacterium leprae | probable zinc metalloprotease | 0.0109 | 0.0478 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 0.0478 | 1 |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.1182 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0243 | 0.0667 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0733 | 0.6021 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0243 | 0.0667 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.1182 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0243 | 0.0667 |
Schistosoma mansoni | family M13 unassigned peptidase (M13 family) | 0.0109 | 0.0478 | 0.0478 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 0.0478 | 1 |
Mycobacterium tuberculosis | Probable zinc metalloprotease Zmp1 | 0.0109 | 0.0478 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.0243 | 0.0667 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.1182 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.